TITLE

Two Doses of a Lipid Formulation of Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis

AUTHOR(S)
Syriopoulou, Vassiliki; Daikos, George L.; Theodoridou, Maria; Pavlopoulou, Ioanna; Manolaki, Archondia G.; Sereti, Evergelia; Karamboula, Aikaterini; Papathanasiou, Dimitra; Krikos, Xenophon; Saroglou, George
PUB. DATE
March 2003
SOURCE
Clinical Infectious Diseases;3/1/2003, Vol. 36 Issue 5, p560
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To evaluate the efficacy of a short course of a lipid formulation of amphotericin B (L-AmB) for the treatment of Mediterranean visceral leishmaniasis (VL), an open prospective study was conducted. Forty-one children with parasitologically confirmed leishmaniasis received L-AmB, 10 mg/kg daily for 2 days. The comparison groups were 30 children who, in a previous study, were treated with L-AmB, 4 mg/kg daily for 5 days, and 52 children who were treated with meglumine antimoniate. At 6 months after completion of treatment, overall treatment success was noted for 40 of 41 children treated with 2 doses of L-AmB, 27 of 30 children treated with 5 doses of L-AmB, and 47 of 52 children treated with meglumine antimoniate. Abatement of fever, reduction in spleen size, and correction of laboratory parameters occurred more quickly among the children who received 2 doses of L-AmB than among the comparison groups, and the total estimated cost of the 2-dose regimen was also lower than that of the other regimens. Two doses of L-AmB, 10 mg/kg each, is cost-effective therapy for Mediterranean VL in children.
ACCESSION #
9424772

 

Related Articles

  • Lipid Droplet Formation, Their Localization and Dynamics during Leishmania major Macrophage Infection. Rabhi, Sameh; Rabhi, Imen; Trentin, Bernadette; Piquemal, David; Regnault, Béatrice; Goyard, Sophie; Lang, Thierry; Descoteaux, Albert; Enninga, Jost; Guizani-Tabbane, Lamia // PLoS ONE;2/12/2016, Vol. 11 Issue 2, p1 

    Leishmania, the causative agent of vector-borne diseases, known as leishmaniases, is an obligate intracellular parasite within mammalian hosts. The outcome of infection depends largely on the activation status of macrophages, the first line of mammalian defense and the major target cells for...

  • In Afghanistan, Tackling Leishmaniasis--and Narcotics.  // UN Chronicle;Mar-May2003, Vol. 40 Issue 1, p63 

    Focuses on the risk of leishmaniasis parasite infection among women and children in Kabul, Afghanistan. Resistance levels of returning refugees; Appeal launched by the World Health Organization for funds; Need of funding to launch a program for the prevention of leishmaniasis.

  • New World leishmaniasis from Spain. N Tomson // Postgraduate Medical Journal;Dec2002, Vol. 78 Issue 926, p757 

    A 69 year old man living in Spain contracted mucocutaneous leishmaniasis involving the nose. The infecting organism was Leishmania infantum, which only rarely causes the New World form of the disease. The source of infection was probably a neighbour's dog. The patient began treatment with...

  • NEONATAL LEISHMANIASIS. E., Bonifazi // European Journal of Pediatric Dermatolgy;Apr2010, Vol. 20 Issue 2, p149 

    The article describes a case of neonatal leishmaniasis diagnosed in a 17-month-old girl in Italy.

  • Paromomycin.  // Reactions Weekly;6/16/2012, Issue 1406, p30 

    The article describes the case of a 40-year-old woman who experienced post kala-azar dermal leishmaniasis (PKDL) after receiving paromomycin.

  • Metabolomics to Unveil and Understand Phenotypic Diversity between Pathogen Populations. t'Kindt, Ruben; Scheltema, Richard A.; Jankevics, Andris; Brunker, Kirstyn; Rijal, Suman; Dujardin, Jean-Claude; Breitling, Rainer; Watson, David G.; Coombs, Graham H.; Decuypere, Saskia // PLoS Neglected Tropical Diseases;Nov2010, Vol. 4 Issue 11, p1 

    Leishmaniasis is a debilitating disease caused by the parasite Leishmania. There is extensive clinical polymorphism, including variable responsiveness to treatment. We study Leishmania donovani parasites isolated from visceral leishmaniasis patients in Nepal that responded differently to...

  • Terpenes Increase the Lipid Dynamics in the Leishmania Plasma Membrane at Concentrations Similar to Their IC50 Values. Camargos, Heverton Silva; Moreira, Rodrigo Alves; Mendanha, Sebastião Antonio; Fernandes, Kelly Souza; Dorta, Miriam Leandro; Alonso, Antonio // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Although many terpenes have shown antitumor, antibacterial, antifungal, and antiparasitic activity, the mechanism of action is not well established. Electron paramagnetic resonance (EPR) spectroscopy of the spin-labeled 5-doxyl stearic acid revealed remarkable fluidity increases in the plasma...

  • LXR Deficiency Confers Increased Protection against Visceral Leishmania Infection in Mice. Bruhn, Kevin W.; Marathe, Chaitra; Maretti-Mira, Ana Cláudia; Hong Nguyen; Haskell, Jacquelyn; Thu Anh Tran; Vanchinathan, Veena; Gaur, Upasna; Wilson, Mary E.; Tontonoz, Peter; Craft, Noah // PLoS Neglected Tropical Diseases;Nov2010, Vol. 4 Issue 11, p1 

    Background: The liver X receptors (LXRs) are a family of nuclear receptor transcription factors that are activated by oxysterols and have defined roles in both lipid metabolism and cholesterol regulation. LXRs also affect antimicrobial responses and have anti-inflammatory effects in macrophages....

  • Epidemiological study of reservoir hosts in an endemic area of zoonotic cutaneous leishmaniasis... Yaghoobi-Ershadi, M.R.; Javadian, E. // Bulletin of the World Health Organization;1996, Vol. 74 Issue 6, p587 

    Determines the ecology of natural reservoir hosts of leishmaniasis for possible field trials of leishmania vaccine in the central part of Islamic Republic of Iran. Different reservoir hosts; Varying rates of infection in different villages; Role of rodents; Recommendation of implementing...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics